Taxifolin and gastro-adhesive microparticles containing taxifolin promotes gastric healing in vivo, inhibits Helicobacter pylori in vitro and proton pump reversibly in silico

Moura, Fernanda Cristina Stenger; Cechinel‐Filho, Valdir; Greco, Francesco; Venzon, Larissa; Meurer, Mariane; França, Tauani Caroline dos Santos; Longo, Bruna; Somensi, Líncon Bordignon; Mariano, Luísa Nathália Bolda; Cruz, Alexandre Bella; Macchiarulo, Antonio; Schoubben, Aurelie Marie Madeleine; Ricci, Maurizio; Bresolin, Tania Mari Bellé; Silva, Luísa Mota da

doi:10.1016/j.cbi.2021.109445

Cited by 13 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, this compound from a similar study also demonstrated an MBC against H. pylori ranging from 2.5 to 10 µg/mL. A high MIC value ≥500 µg/mL was reported in the studies that examined the antibacterial activity of the compound taxifolin from Mimusops balata fruit [25], the ethyl acetate fraction of Physalis alkekengi L. var. franchetii, and the dry extract of Libidibia ferrea.…”

Section: Antibacterial Activity Of Natural Products From Plants and N...mentioning

confidence: 61%

The Potential of Alternative Therapies and Vaccine Candidates against Helicobacter pylori

et al. 2023

View full text Add to dashboard Cite

Alternative therapies and vaccination are essential to combat the emergence of multidrug-resistant Helicobacter pylori and to prevent the development of gastroduodenal diseases. This review aimed to systematically review recent studies on alternative therapies, i.e., probiotics, nanoparticles, and natural products from plants, as well as recent progress in H. pylori vaccines at the preclinical stage. Articles published from January 2018 to August 2022 were systematically searched using PubMed, Scopus, Web of Science, and Medline. After the screening process, 45 articles were eligible for inclusion in this review. Probiotics (n = 9 studies) and natural products from plants (n = 28 studies) were observed to inhibit the growth of H. pylori, improve immune response, reduce inflammation, and reduce the pathogenic effects of H. pylori virulence factors. Natural products from plants also showed anti-biofilm activity against H. pylori. However, clinical trials of natural products from plants and probiotics are still lacking. A paucity of data assessing the nanoparticle activity of N-acylhomoserine lactonase-stabilized silver against H. pylori was observed. Nonetheless, one nanoparticle study showed anti-biofilm activity against H. pylori. Promising results of H. pylori vaccine candidates (n = 7) were observed at preclinical stage, including elicitation of a humoral and mucosal immune response. Furthermore, the application of new vaccine technology including multi-epitope and vector-based vaccines using bacteria was investigated at the preclinical stage. Taken together, probiotics, natural products from plants, and nanoparticles exhibited antibacterial activity against H. pylori. New vaccine technology shows promising results against H. pylori.

show abstract

Section: Antibacterial Activity Of Natural Products From Plants and N...mentioning

confidence: 61%

The Potential of Alternative Therapies and Vaccine Candidates against Helicobacter pylori

et al. 2023

View full text Add to dashboard Cite

show abstract

“…В одном исследовании на модели хронической язвы желудка у крыс было продемонстрировано гастропротективное свойство таксифолина (дигидрокверцетина), пероральный прием которого уменьшал размер язвы желудка на 63% по сравнению с контрольной группой, получавшей омепразол (на 57%), при этом был зафиксирован дозозависимый эффект таксифолина. Отмечено ингибирующее влияние таксифолина на H. pylori in vitro [40], вероятно обусловленное повреждением клеточной оболочки грамотрицательных бактерий [41,42]. Авторы рассматривают эти результаты в качестве свидетельства противоязвенного эффекта таксифолина, обусловленного стимулированием защитных факторов желудка (усиление продукции слизи, снижение активности миелопероксидазы и повышение содержания восстановленного глутатиона в области язвы), а также его ингибирующим воздействием на H + /K + -АТФазу и H. pylori [40].…”

Section: Discussionunclassified

“…Отмечено ингибирующее влияние таксифолина на H. pylori in vitro [40], вероятно обусловленное повреждением клеточной оболочки грамотрицательных бактерий [41,42]. Авторы рассматривают эти результаты в качестве свидетельства противоязвенного эффекта таксифолина, обусловленного стимулированием защитных факторов желудка (усиление продукции слизи, снижение активности миелопероксидазы и повышение содержания восстановленного глутатиона в области язвы), а также его ингибирующим воздействием на H + /K + -АТФазу и H. pylori [40].…”

Section: Discussionunclassified

Efficacy and Safety Evaluation of Gastrokur Dietary Supplement in Combination with Pantoprazole in Patients with Helicobacter pylori

Bordin¹,

Voynovan²

2022

EPh

View full text Add to dashboard Cite

The results of a clinical study of the efficacy and safety of taking a dietary supplement Gastrokur in combination with pantoprazole in patients with Helicobacter pylori are presented. Material and methods. 10 patients with H. pylori infection confirmed according to 13C-urease respiratory test for four weeks received the dietary supplement Gastrokur two capsules three times a day in combination with pantoprazole 40 mg once a day. A special condition was the compliance with Gastrokur temperature regime of storage from +40 to +100 С. The efficacy of eradication was evaluated using a 13C urease breath test 30 days after completion of treatment. Results. H. pylori eradication was achieved in two out of 10 (20%) patients according to the ITT criterion and in two out of nine (22.2%) patients according to the PP criterion. By the 14th day of therapy, 80% of patients had completely stopped symptoms of dyspepsia with the effect remaining for a month after the end of therapy. During the first two weeks of therapy, three patients had bloating, five had mushy stools no more than three times a day. These phenomena were not pronounced and did not require interruption of treatment. One patient dropped out of the study due to an exacerbation of pink lichen on the 21st day of therapy, which independently passed two days after discontinuation of treatment. Conclusion. A course of therapy with a biologically active food supplement Gastrokur in combination with pantoprazole led to the eradication of H. pylori in 20%. Against the background of therapy, a good positive clinical dynamics was observed. No serious adverse events have been reported, with the exception of an exacerbation of pink lichen in one patient.

show abstract

“…(MIC = 625 μg/mL). C et al believe that the oral treatment of acidic digestive diseases may offer significant promise ( Stenger Moura et al, 2021a ).…”

Section: Therapeutic Effects Of Taxifolinmentioning

confidence: 99%

An insight into novel therapeutic potentials of taxifolin

et al. 2023

View full text Add to dashboard Cite

Taxifolin is a flavonoid compound, originally isolated from the bark of Douglas fir trees, which is often found in foods such as onions and olive oil, and is also used in commercial preparations, and has attracted the interest of nutritionists and medicinal chemists due to its broad range of health-promoting effects. It is a powerful antioxidant with excellent antioxidant, anti-inflammatory, anti-microbial and other pharmacological activities. This review focuses on the breakthroughs in taxifolin for the treatment of diseases from 2019 to 2022 according to various systems of the human body, such as the nervous system, immune system, and digestive system, and on the basis of this review, we summarize the problems of current research and try to suggest solutions and future research directions.

show abstract

Taxifolin and gastro-adhesive microparticles containing taxifolin promotes gastric healing in vivo, inhibits Helicobacter pylori in vitro and proton pump reversibly in silico

Cited by 13 publications

References 55 publications

The Potential of Alternative Therapies and Vaccine Candidates against Helicobacter pylori

The Potential of Alternative Therapies and Vaccine Candidates against Helicobacter pylori

Efficacy and Safety Evaluation of Gastrokur Dietary Supplement in Combination with Pantoprazole in Patients with Helicobacter pylori

An insight into novel therapeutic potentials of taxifolin

Contact Info

Product

Resources

About